Avastin News and Research

RSS
Avastin is a biologic antibody designed to specifically bind to a protein called vascular endothelial growth factor (VEGF) that plays an important role throughout the lifecycle of the tumor to develop and maintain blood vessels, a process known as angiogenesis. Avastin is designed to interfere with the blood supply to a tumor by directly binding to the VEGF protein to prevent interactions with receptors on blood vessel cells. Avastin does not bind to receptors on normal or cancer cells. The tumor blood supply is thought to be critical to a tumor’s ability to grow and spread in the body (metastasize).
Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

Avastin approval to drive ovarian cancer drug market to $1.5 billion in 2018

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

Keryx Biopharmaceuticals' perifosine receives FDA Fast Track Designation

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

FDA grants Keryx Biopharmaceuticals Fast Track designation for perifosine

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Rosetta Genomics' Philadelphia lab commences FNA cell block sample analysis with miRview squamous test

Prescription drug spending up in 2009

Prescription drug spending up in 2009

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

Strong demand leads to 5.1% growth in 2009 U.S. sales of ethical pharmaceuticals

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

Bevacizumab/paclitaxel/carboplatin regimen attains gold-standard status for treatment of non-small-cell lung cancer

AVASTIN receives Health Canada approval for patients with GBM

AVASTIN receives Health Canada approval for patients with GBM

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Stage IV colorectal cancer: Therapy that improves overall survival over IFL/bevacizumab will earn 60% patient share

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Latest treatment options for colorectal cancer highlighted at NCCN Annual Conference

Genentech announces topline results from Phase III trial of Avastin

Genentech announces topline results from Phase III trial of Avastin

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Idera Pharmaceuticals announces net income of $3.9M for fourth-quarter 2009

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Data from FAME Phase 3 study for Iluvien presented at Angiogenesis 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Genentech's Avastin combination Phase III study in advanced stomach cancer does not meet primary endpoint

Antigenics announces fourth-quarter and full-year 2009 financial results

Antigenics announces fourth-quarter and full-year 2009 financial results

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Sorafenib drug therapy can reduce the size of primary kidney tumors before surgery

Cancer drug could be effective for treating recurrent nose bleeds

Cancer drug could be effective for treating recurrent nose bleeds

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

Keryx Biopharmaceuticals reaches agreement with FDA on SPA for Phase 3 trial of KRX-0401

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.